

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	4335469
<b>Application Number:</b>	10528073
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	2784
<b>Title of Invention:</b>	Obtaining and Use of Therapeutic Antibodies Entering Into the Cell
<b>First Named Inventor/Applicant Name:</b>	Andres Valkna
<b>Customer Number:</b>	02292
<b>Filer:</b>	Esther Hyeri Chong/Sheryll Jenkins
<b>Filer Authorized By:</b>	Esther Hyeri Chong
<b>Attorney Docket Number:</b>	0552-0160PUS1
<b>Receipt Date:</b>	21-NOV-2008
<b>Filing Date:</b>	17-MAR-2005
<b>Time Stamp:</b>	16:29:36
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$735
RAM confirmation Number	1970
Deposit Account	022448
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

**File Listing:**

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		2008-11-21Amend.pdf	5113496 d49d1b7cc01621b613be9bd5432cedf88270679	yes	33
<b>Multipart Description/PDF files in .zip description</b>					
	<b>Document Description</b>		<b>Start</b>		<b>End</b>
	Miscellaneous Incoming Letter		1		1
	Extension of Time		2		2
	Amendment/Req. Reconsideration-After Non-Final Reject		3		3
	Specification		4		6
	Sequence Listing		7		7
	Claims		8		9
	Applicant Arguments/Remarks Made in an Amendment		10		22
	Applicant Arguments/Remarks Made in an Amendment		23		28
	Sequence Listing		29		30
	Application Data Sheet		31		33
<b>Warnings:</b>					
<b>Information:</b>					
2		2008-11-21IDS.pdf	1114605 5562ba1728cc7419a7227863e3eddbf84f1032a095df	yes	6
<b>Multipart Description/PDF files in .zip description</b>					
	<b>Document Description</b>		<b>Start</b>		<b>End</b>
	Information Disclosure Statement Letter		1		5
	Information Disclosure Statement (IDS) Filed (SB/08)		6		6
<b>Warnings:</b>					
<b>Information:</b>					

3	NPL Documents	2008-11-21ref-proteintransduction.pdf	1777671 55ce490637dbb36d3715ca702715c43c9349f	no	6
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	2008-11-21-refmolecular.pdf	10016017 d97cd306619f75cd77033d18b6e819d16d2a5237a	no	30
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	2008-11-21-refantibody.pdf	2621913 675ab46fc18f90310c4712866d4bce2bb159d48	no	8
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	20081121drugdiscovery.pdf	2221755 1fb6eb2c5a1be5a7e0d117d8d4b631255e07a8ba	no	7
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	20081121deletionanalogues.pdf	3255142 ce012d3d87e64aa38618111a17ee16481d362	no	12
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	20081121refbasall.pdf	1407768 caca3e6486cd49957a1d5a65c9796558f796a0	no	5
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	20081121refcargo.pdf	2354228 f965a6d8d770atab0ff313b1d4263cd485a67ca	no	9
<b>Warnings:</b>					
<b>Information:</b>					
10	Sequence Listing (Text File)	20081120SequenceListing.txt	1965	no	0
<b>Warnings:</b>					
<b>Information:</b>					
11	Fee Worksheet (PTO-06)	fee-info.pdf	31816 ee6ef275f63b656676d31851cd63917a79e39	no	2
<b>Warnings:</b>					
<b>Information:</b>					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.